Keyword: Susan Collins

The Democrats' new drug pricing bills are "flawed"—and likely to fail—unless Trump crosses the aisle. And as one analyst sees it, he just might.

Democrats rolled out their new economic agenda Monday, calling it a “Better Deal.” For consumers, maybe. For the pharma industry, not so much.

After a week scrabbling to calm the EpiPen pricing crisis, Mylan has unveiled its latest tactic. The drugmaker plans to launch an authorized generic priced at less than half the cost of the brand.

It didn’t take long for the backlash to start after Mylan crafted an EpiPen patient-assistance plan to calm the pricing crisis. Critics pounced, calling the tactic “inadequate and cynical.”

The power of a Hillary Clinton tweet showed again Wednesday, when the presidential candidate spoke on drug price, raising fears of government action. Biotech stocks, pharma stocks--even U.K. drugmakers suffered.

Amid a frenzy of criticism for the price of EpiPen, Mylan swiftly expanded its co-pay help for patients. But it did not adjust the actual price of a med that’s more than 400% more expensive than it was in 2009.